You are here

Press Releases

Nov 11, 2015

New Data Presented at American Heart Association’s Scientific Sessions

New Haven, CT, November 10, 2015 – New Haven Pharmaceuticals, Inc. today announced new study data that shows the company’s FDA-approved drug DURLAZA™ delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

DURLAZA™ is the first prescription, low dose, extended-release aspirin, (162.5mg), for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack).

Nov 02, 2015

New Haven, CT, November 2nd, 2015 – New Haven Pharmaceuticals, Inc. today announced it will present study results regarding antiplatelet effects of its FDA-approved drug DURLAZA™ at the upcoming American Heart Association Scientific Sessions event.

Oct 06, 2015

Loan Supports Go-To-Market Strategy for FDA Approved DURLAZA™


Subscribe to News